Today's stock selection:
SCRX
Inspired by:
http://www.zacks.com/newsroom/...
Sciele Pharma, Inc. (SCRX) is a specialty pharmaceutical
company engaged in the sale of prescription products for the
treatment of cardiovascular, metabolic, obstetrical and
gynecological, and pediatric and gastroenterological
conditions and disorders. The company s broad focus and
deep product pipeline offer substantial growth opportunities
over the next several years. Moreover, Sciele received a
boost in January when the FDA approved the company s
new Sular formulation. This removed a significant overhang
from the stock. Sciele started shipping and promoting the
new Sular from late March
the company intends to switch
users to the new formulation prior to the potential entry of
generic Sular. We believe the current share price represents
an attractive entry point for long-term investors and we rate
the stock a Buy. We recommend purchase up to the $28
level
http://astuk-virtuallystocks.blogspot.com/
$19.36 (06/12/08)
